A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

FIZE Medical Completes $5.3 Million Series A Financing

April 6, 2021

FIZE Medical, Inc. recently closed a Series A financing led by Rapha Capital Management, LLC an investment management firm located in Miami, Florida, through Rapha Capital Investment IX, LLC  (an entity managed by Rapha Capital).

RCI IX was joined in the lead by MIG FZ LLC, led by Michael Ingber MD, Director of The Center for Specialized Women’s Health at Garden State Urology, within the Atlantic Health System.  This second, final tranche of financing completes FIZE’s Series A financing, initiated with the first tranche closing in May 2020.  The total $5.3 million financing will be used to further develop and commercialize FIZE’s novel device, the iUO, the first accurate, automatic, digital, and cost-effective device to measure urine output in real-time, replacing the current, manually managed, urinometer bag attached to a standard Foley catheter, to be made available to hospitals and physicians worldwide.  Rapha Capital’s inaugural first managed VC Fund, Rapha Capital BioVentures Fund I also participated in this financing.

Rapha Capital Management is an investment management firm focused on managing strategic investments in early-stage, non-public biotechnology companies, previously through special-purpose investment vehicles (“SPIVs”).

Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon.  After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies.  He is the founder of Bellicum Pharmaceuticals, Inc., a publicly-traded company listed on NASDAQ, leading Bellicum to a successful $161 million IPO in December 2014.

He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc., FIZE Medical, Inc., and Demeetra AgBio, Inc. He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid-2020.

Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII.  Rapha Capital Management will be offering alternative asset management services to its inaugural venture capital fund, launching April 15th, 2021, which will be the vehicle for all future investments managed by Rapha Capital Management.

“FIZE’s basic device, the iUO™, by itself is a giant leap forward in medicine, conquering the last frontier inpatient monitoring by digitizing urine output, measured in real-time, and placing it at the physicians’ fingertips,” said Kevin Slawin MD.  “FIZE’s vision, to be delivered through its pipeline of follow-on products, the iUO PLUS ™, and iUO DUOFLO ™, is poised to truly transform medicine by adding acute kidney injury (AKI) and shock prediction, core temperature, and intraabdominal pressure monitoring (IAP), fluid balance and diuretic use and monitoring, real-time urinalysis and UTI management, and automated intravesical chemotherapy and continuous bladder irrigation (CBI) therapy to the iUO™’s core capabilities,” he added.

“It’s been gratifying to see how Urologists, including our lead investors Drs. Slawin and Ingber, who understand better than most the optimal management of Foley catheters, respond with such excitement and commitment to our company’s technology and the advances it offers to their patients,” said Dror Zerem, CEO of FIZE Medical.

The COVID 19 pandemic has led to a realization of the need to prioritize technologies that increase the protection of healthcare workers, while improving the care of critically ill patients, and providing enhanced efficiency. The FIZE® iUO™ device addresses all of these goals by reducing the number of times a nurse/healthcare worker needs to enter the room of an infected patient by automating bladder management.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy